Viridian closes $289M equity, $300M royalty financing; BLA submitted for veligrotug in TED

Viridian Therapeutics, Inc.\DE

Cash position ~$887.9M as of Oct 31, 2025, up from $490.9M at Sep 30, after equity, royalty, and debt financings.
BLA for veligrotug (IV) in thyroid eye disease submitted to FDA Oct 2025 with Priority Review request; mid-2026 launch targeted if approved.
Subcutaneous VRDN-003 topline data accelerated: REVEAL-1 in Q1 2026, REVEAL-2 in Q2 2026; both trials exceeded enrollment targets (132 and 204 patients).
R&D expenses $86.3M in Q3 2025 (up 25% YoY) driven by Ph3 programs; G&A $24.3M (up 69% YoY) from launch prep.
VRDN-006 showed IgG reduction proof-of-concept in Ph1; VRDN-008 IND on track for year-end 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.